01/04/2026 Alkermes announced initiation of Phase 3 Brilliance studies evaluating alixorexton for NT1 and NT2 Alkermes announced initiation of Phase 3 Brilliance studies evaluating alixorexton for NT1 and NT2 ( Ref ) Alkermes announced the initiation of the Phase 3 Brilliance studies program, which evaluated  the safety and efficacy of alixorexton (ALKS 2680; selective OX2R agonist) for the treatment of adult patients with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) T

10/02/2026 US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy for Narcolepsy Type 1 Evommune reported positive top-line data from Phase 2a POC trial of EVO301 in moderate-to-severe atopic dermatitis Kincell Bio partnered with Regcell to advance Treg cell therapies into clinical trials for autoimmune diseases US FDA accepted NDA and granted priority review for Takeda’s oveporexton as a potential first-in-class therapy